EUCTR2011-001429-25-NL
Active, not recruiting
Not Applicable
Feasibility Study: FES-PET to determine ER-expression in epithelial ovarian cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity Medical Center Groningen
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Histological evidence or high clinical suspicion with proven malignant ascites and high probability of epithelial ovarian cancer
- •2\.The presence of at least one measurable lesion (RECIST v1\.1\).
- •3\.Histology or cytology can be obtained (may be ascites)
- •4\.ECOG performance status 0\-2\.
- •5\.Postmenopausal status (defined as either \>45 years with amenorrhea \>12 months, or prior bilateral ovariectomy)
- •6\.No history of other ER\-positive malignancies
- •7\.Signed written informed consent
- •8\.Able to comply with the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
Exclusion Criteria
- •1\.Use of estrogen receptor ligands, including tamoxifen, fulvestrant or estrogens, during the 5 weeks before entry into the study
- •2\.Life\-expectancy \= 3 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-a status in patients with metastatic breast cancer HER2 + and ERa neg treated with trastuzumab + pertuzumab + taxane.Metastatic breast cancer HER2 + and ERa neg.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001552-36-FRINSTITUT CLAUDIUS REGAUD33
Completed
Not Applicable
Examination of Clinical usefulness of FES-PET for hormone therapy against recurrence after adjuvant hormone therapy of estrogen receptor-positive breast cancerRecurrence of estrogen-positive breast cancerJPRN-UMIN000016488Institusion of Biomedical Resarch and Innovation10
Withdrawn
Phase 2
Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PETBreast CancerNCT03065712University of Texas Southwestern Medical Center
Completed
Not Applicable
A pilot study of FES-PET for patients with breast cancerbreast cancerJPRN-UMIN000003124Institute of Biomedical Research and Innovation5
Terminated
Not Applicable
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.HER2-positive Breast CancerNCT03619044Institut Claudius Regaud4